Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

被引：0
|
作者：
Rummel, Mathias J.
Buske, Christian
Hertenstein, Bernd
Lerchenmueller, Christian
Koenigsmann, Michael
Lange, Elisabeth
Reeb, Manfred
Kaiser, Ulrich
Balser, Christina
Behringer, Dirk
Durig, Jan
Gaska, Tobias
Maschmeyer, Georg
Schliesser, Georg
Burchardt, Alexander Christoph
Barth, Juergen
Kauff, Frank
Hinke, Axel
Greil, Richard
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
483
引用
收藏
页数：3
相关论文
共 49 条
  • [1] Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)
    Rummel, M.
    Buske, C.
    Hertenstein, B.
    Lerchenmueller, C. A.
    Koenigsmann, M.
    Lange, E.
    Reeb, M.
    Kaiser, U.
    Balser, C.
    Behringer, D.
    Duerig, J.
    Gaska, T.
    Maschmeyer, G.
    Schliesser, G.
    Burchardt, A.
    Barth, J.
    Kauff, F.
    Hinke, A.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 251 - 251
  • [2] Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)
    Rummel, Mathias
    Buske, Christian
    Hertenstein, Bernd
    Lerchenmueller, Christian
    Koenigsmann, Michael
    Lange, Elisabeth
    Reeb, Manfred
    Kaiser, Ulrich
    Balser, Christina
    Behringer, Dirk
    Duerig, Jan
    Gaska, Tobias
    Maschmeyer, Georg
    Schliesser, Georg
    Burchardt, Alexander C.
    Barth, Juergen
    Kauff, Frank
    Hinke, Axel
    Greil, Richard
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S101 - S103
  • [3] Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).
    Rummel, Mathias J.
    Knauf, Wolfgang
    Goerner, Martin
    Soeling, Ulrike
    Lange, Elisabeth
    Hertenstein, Bernd
    Eggert, Jochen
    Schliesser, Georg C.
    Weide, Rudolf
    Blumenstengel, Klaus
    Detlefsen, Ninia
    Hinke, Axel
    Kauff, Frank
    Barth, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).
    Rummel, Mathias J.
    Koenigsmann, Michael
    Chow, Kai Uwe
    Knauf, Wolfgang
    Lerchenmuller, Christian A.
    Losem, Christoph
    Goerner, Martin
    Hertenstein, Bernd
    Decker, Thomas
    Ganser, Arnold
    Gaska, Tobias
    Heike, Michael
    Lange, Elisabeth
    Weide, Rudolf
    Willenbacher, Wolfgang
    Burchardt, Alexander
    Kauff, Frank
    Barth, Juergen
    Hinke, Axel
    Greil, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Two years Rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)
    Rummel, M.
    Koenigsmann, M.
    Chow, K. U.
    Knauf, W.
    Lerchenmueller, C. A.
    Losem, C.
    Goerner, M.
    Hertenstein, B.
    Decker, T.
    Ganser, A.
    Gaska, T.
    Heike, M.
    Lange, E.
    Weide, R.
    Willenbacher, W.
    Burchardt, A.
    Kauff, F.
    Barth, J.
    Hinke, A.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 253 - 253
  • [6] Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstrom's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
    Rummel, Mathias J.
    Lerchenmueller, Christian
    Hensel, Manfred
    Goerner, Martin
    Buske, Christian
    Schulz, Holger
    Schmidt, Burkhard
    Kojouharoff, Georgi
    Lange, Elisabeth
    Willenbacher, Wolfgang
    Durig, Jan
    Engel, Erik
    Kauff, Frank
    Barth, Jurgen
    Burchardt, Alexander Christoph
    Hinke, Axel
    Wupperfeld, Jasmin
    Greil, Richard
    BLOOD, 2019, 134
  • [7] Two Years Rituximab Maintenance Vs Observation After First Line Treatment With Bendamustine Plus Rituximab in Patients With Waldenstrom's Macroglobulinemia: Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 23 - 23
  • [8] Two years Rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial; Clinicaltrials.gov Identifier: NCT00877214)
    Rummel, M.
    Knauf, W.
    Goemer, M.
    Soeling, U.
    Lange, E.
    Hertenstein, B.
    Eggert, J.
    Schliesser, G. C.
    Weide, R.
    Blumenstengel, K.
    Detlefsen, N.
    Hinke, A.
    Kauff, F.
    Barth, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 118 - 118
  • [9] 10-year updated results from the StiL NHL1 study bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas
    Rummel, M. J.
    Maschmeyer, G.
    Ganser, A.
    Heider, A.
    von Gruenhagen, U.
    Losem, C.
    Heil, G.
    Welslau, M.
    Balser, C.
    Kaiser, U.
    Weidmann, E.
    Duerk, H. A.
    Ballo, H.
    Stauch, M.
    Blau, W.
    Burchardt, A.
    Barth, J.
    Kauff, F.
    Brugger, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 73 - 73
  • [10] Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL)-7 Year Updated Results from the StiL NHL1 Study
    Rummel, Mathias J.
    Maschmeyer, Georg
    Ganser, Arnold
    Heider, Andrea
    von Gruenhagen, Ulrich
    Losem, Christoph
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz
    Boeck, Hans Peter
    Stauch, Martina Beate
    Barth, Juergen
    Blau, Wolfgang
    Burchardt, Alexander
    Kauff, Frank
    Hinke, Axel
    Brugger, Wolfram
    BLOOD, 2014, 124 (21)
12345